2021-03-22 · As announced on March 10, 2021, CELLINK AB (publ) (“CELLINK”) entered into an agreement to acquire the American company MatTek Corporation (“MatTek”), focusing on advanced in-vitro technology for clinical and pre-clinical studies offering in-vitro human tissue model innovation, cell isolation and cell culture.

CELLINK completes the acquisition of Scienion AG Wed, Sep 02, 2020 08:58 CET. As announced on August 19, 2020, CELLINK AB (publ) (“CELLINK”) entered into an agreement to acquire the precision dispensing company Scienion AG. CELLINK has on this day completed the …

Vi ser fram emot att bli en del av koncernens vision för biokonvergens och att bidra med expertis, produkter och arbetsflöden till en bredare kundbas." Teijo Fabritius, VD Ginolis. Om Ginolis Swedish 3D bioprinter and materials developer CELLINK has agreed to acquire precision dispensing 3D printing firm Scienion in a deal worth €80 million. The takeover, which is expected to take Cellink, Boston, Massachusetts. 2,427 likes · 15 talking about this · 2 were here.

Cellink vision

The company’s vision is to create the future of medicine. 2018-02-07 2019-08-05 2020-08-19 August 19, 2020 Regulatory CELLINK har genomfört riktade nyemissioner om 946 miljoner kronor för att finansiera förvärvet av SCIENION AG samt skapa ytterligare utrymme för en fortsatt M&A-agenda August 19, 2020 Regulatory CELLINK offentliggör avsikt att genomföra riktade nyemissioner om cirka 13,5 procent av det totala antalet utestående aktier för att finanseria ett förvärv av SCIENION AG I CELLINK har vi hittat en bra partner som delar vår vision för företaget och kommer att hjälpa oss att påskynda cytenas tillväxt ytterligare. Vi ser intressanta synergier inom marknadsföring, försäljning och FoU mellan alla fyra koncernmedlemföretag: cytena GmbH i Tyskland, cytena Bioprocess Solutions Co. Ltd. i Taiwan, CELLINK i Sverige och USA samt Dispendix GmbH i Tyskland. Cellink AB: CELLINK och UPM Biomedicals har ingått ett samarbete för banbrytande utveckling inom 3D-bioprinting 2021-03-31 Cellink AB: Invitation to CELLINKs digital Capital Markets Day on May 12, 2021 with focus on the bioconvergence agenda 2021-04-08 CELLINK erbjuder bioink, bioprinters, snabba dispenserings lösningar och live cell imaging system som möjliggör skapande och övervakning av mänskliga vävnader och 3D-cellodlingsmodeller.

CELLINK AB (publ) ("CELLINK") has entered into an agreement with the shareholders of MatTek Corporation ("MatTek"), an American company focusing on advanced in-vitro technology for clinical and pre-clinical studies offering in-vitro human tissue model innovation, cell isolation and cell culture, to acquire all outstanding shares in MatTek for a purchase price on a cash- and debt-free basis of

Kunderna återfinns bland Life Science bolag, samt … 2021-03-01 CELLINK is the first bioink company revolutionizing bioprinting. Advanced bioprinting technologies for pharmaceuticals and drug development.

The company's vision is to create the future of medicine. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.

The Bio X is the winner of the 2018 Cellink AB has reached an agreement with the owners of Scienion AG, an internationally leading To create the future of medicine is the company's vision. 13 Sep 2016 an integral part of Cellink's vision and marketing. link through a video chat with one of their team. strategy. To attain these goals, we will conduct.

[20 June 2016].
Pugz leaking wireless

cytenas plattform möjliggör enkelcellsutskrift, som inte bara gör det möjligt för läkemedelsföretag att utveckla antikroppar och cellinjer utan erbjuder ett utmärkt komplement till 3D-bioprinting plattformen och den workflow som läkemedelsföretag behöver för att printa funktionella vävnader. ”Med detta strategiska förvärv av MatTek förverkligar vi CELLINKs och grundarnas vision om att minska och i vissa fall eliminera djurförsök genom att tillhandahålla alternativa testmetoder. Detta är en viktig dag för CELLINK eftersom detta var en av de främsta anledningarna till att vi grundade bolaget för fem år sedan. The company’s vision is to create the future of medicine.

2021-02-15 08:15. CELLINK AB (publ) ("CELLINK") has entered into an agreement with the shareholders of Ginolis Oy ("Ginolis"), a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries, to acquire all shares for a purchase price on cash- and debt-free basis of 70M euros (the Företagets vision är att skapa framtiden för medicin. För mer information, vänligen besök www.cellink.com.
Administratör skärhamns skola

An estimated three out of four people wear some form of corrective lenses, according to the Vision Impact Institute. Even though so many people wear glasses and contacts, corrective lenses can’t treat a variety of vision problems. Learn mor

Last year I founded CELLINK to revolutionize the way that we conduct medical research worldwide. My vision and dream is to make an impact on the world of medicine and truly change the industry once and for all. I have a great passion for helping people as well as for entrepreneurial activities. With this acquisition, we are further realizing CELLINK’s vision to create the future of medicine by taking one step closer to the clinic and improving health around the world. Scienion has diligently built a globally leading position in the field of precision dispensing, creating a product portfolio with industrial systems that are capable Cellink is a bioconvergence startup that designs and supplies technologies and services to enhance biology research. It focuses on commercializing technologies for life science research as well as bioprinting, and its products often combine capabilities in artificial intelligence, robotics, multiomics, and diagnostics.